Multibagger Selection: GPT-6's picks
GPT-6 picked AMPX, BKSY, RCAT, ENVX, OUST with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | GPT-6 |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | AMPX | — | 75% | — | — |
| 2 | BKSY | — | 71% | — | — |
| 3 | RCAT | — | 62% | — | — |
| 4 | ENVX | — | 59% | — | — |
| 5 | OUST | — | 74% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | +21.56% | +20.68% | 1.41x | 0 |
The model's market view
The strongest candidates combine identifiable commercial ramps with enough financial resources to survive execution delays. This selection concentrates on batteries, autonomous systems and satellite intelligence, creating substantial shared exposure to defense procurement and manufacturing execution. Near-term price confirmation is weak. Rankings concern 12-month scenario potential, not an imminent rebound, and none of the multiples represents an expected return.
Why each pick
AMPX
Amprius has the clearest sequence of rapid revenue growth, expanding manufacturing margins and narrowing operating losses in this group. Contract manufacturing can support growth without fully funding owned factories. The threefold scenario nevertheless requires substantial additional revenue and continued premium valuation. Screen 4 uses the documented expansion path below 30% gross margin. Screen 5 is not credited because working-capital demands make the timing of positive free cash flow uncertain. Reference price is a regular-session intraday snapshot at the stated quote time.
BKSY
BlackSky combines a relatively small equity capitalization with observable Gen-3 adoption and operating leverage. Subscription expansion can monetize additional constellation capacity, but satellite spending makes adjusted EBITDA an incomplete measure of economics. Screen 4 is not credited using contribution margins that exclude depreciation, and screen 5 is not credited because positive FCF within 12 months remains unverified. Reference price is a regular-session intraday snapshot.
RCAT
Red Cat offers substantial valuation sensitivity to successful drone and maritime-system scaling, with significant cash raised to finance the attempt. Revenue and gross margin have improved, but operating costs and cash consumption have risen sharply. It is a manufacturing-conversion thesis with a large execution gap. Screens 4 and 5 are not credited: margins remain low and a sufficiently evidenced FCF-breakeven timetable is absent. Reference price is a regular-session intraday snapshot.
ENVX
Enovix has a small equity capitalization relative to the commercial opportunity if defense batteries scale and consumer qualifications succeed. The latest disclosures provide an actual order and a dated capacity expansion, improving the evidence beyond a technology-only thesis. Margins and FCF remain inadequate, so screens 4 and 5 are not credited despite substantial liquidity. Reference price is a regular-session intraday snapshot.
OUST
Ouster has stronger demonstrated margins and funding than most candidates, with revenue growth translating into smaller adjusted EBITDA losses. Its larger starting valuation makes extreme appreciation harder, explaining the lower ranking despite comparatively strong evidence quality. Screen 5 reflects a conditional cash-flow bridge and ample funding, not confirmed FCF profitability. Reference price is a regular-session intraday snapshot.
Other models on the same run
| Model | Picks |
|---|---|
| Claude Opus 5.5 | URGN, AXTI, ETON, INOD, BKSY |
| Gemini 3 Pro | BHVN, SG, SMR, JOBY, RDW |
| Grok 4.5 | NRIX, INOD, LQDA, CELC, APLD |
| Muse Spark 1.1 | KOD, CAPR, IVA, RCUS, TPC |
| DeepSeek | INOD, ONDS, SVRA, AQST, INBX |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.